News - Daiichi Sankyo

Filter

Current filters:

Daiichi Sankyo

Popular Filters

1 to 25 of 87 results

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

04-07-2014

Japanese drug major Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2…

canagliflozinCanagluDaiichi SankyoDiabetesJapanMitsubishi TanabePharmaceuticalRegulationSanofi PasteurVaccines

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

Indian court ruling lifts temporary stay on Sun Pharma takeover of Ranbaxy

26-05-2014

Indian generics drugmaker Sun Pharmaceuticals’ proposed $3.2 billion acquisition of loss-making rival…

Daiichi SankyoGenericsLegalMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Sanford-Burnham and Daiichi Sankyo collaborate on novel cardiovascular-metabolic diseases drug targets

22-05-2014

USA-based Sanford-Burnham Medical Research Institute and Japanese drug major Daiichi Sankyo have entered…

Cardio-vascularDaiichi SankyoMetabolicsPharmaceuticalResearch

Daiichi Sankyo halts nimotuzumab Ph III trial in lung cancer

Daiichi Sankyo halts nimotuzumab Ph III trial in lung cancer

30-04-2014

Japanese drug major Daiichi Sankyo says that it has discontinued the Phase III clinical trial conducted…

Daiichi SankyonimotuzumabOncologyPharmaceuticalResearch

Daiichi Sankyo names Ken Keller as President, US Commercial

Daiichi Sankyo names Ken Keller as President, US Commercial

23-04-2014

Japanese drugmaker Daiichi Sankyo has announced that Ken Keller will join the company as President of…

AmgenBoardroomBusiness FinanceDaiichi SankyoHealth Medical PharmaJapanKen KellerPharmaceuticalPharmaceutical experienceUSA

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

10-03-2014

Japanese drug major Daiichi Sankyo has updated on the H5N1 influenza vaccine project, revealing that…

Asia-PacificDaiichi SankyoJapanPharmaceuticalProductionVaccines

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14-02-2014

Japanese drug companies Daiichi Sankyo and UMN Pharma have signed a collaborative research agreement…

Daiichi SankyoJapanLicensingPharmaceuticalResearchVaccines

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

08-01-2014

Japanese drug major Daiichi Sankyo (TYO: 4568) has submitted a Marketing Authorization Application to…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulation

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo partners in new open innovation business funding

18-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and Mitsubishi UFJ Capital Co have agreed to launch a…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalResearch

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST

02-09-2013

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

1 to 25 of 87 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top